<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="105" ids="17234">Glucose</z:chebi>-dependent insulinotropic <z:chebi fb="7" ids="16670">peptide</z:chebi> (GIP) plays a pivotal role in the regulation of <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>Rates of diet-induced <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are decreased when GIP signalling is disturbed in mice, suggesting that GIP plays a role in the <z:hpo ids='HP_0003674'>onset</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>WNT signalling is linked to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and induces synthesis of the other incretin, glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) </plain></SENT>
<SENT sid="3" pm="."><plain>GLP-1 analogues improve treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients in whom GLP-1 signalling is intact and have captured clinical attention </plain></SENT>
<SENT sid="4" pm="."><plain>GIP levels are altered at the <z:hpo ids='HP_0003674'>onset</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and later on, while GIP signalling is impaired </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, GIP is not a candidate for treatment but might be an important target from a prevention perspective </plain></SENT>
<SENT sid="6" pm="."><plain>Hypothesising that hypersecretion of GIP links altered WNT signalling to the <z:hpo ids='HP_0003674'>onset</z:hpo> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we sought to determine whether WNT signalling induces GIP production by entero-<z:chebi fb="32" ids="24621">endocrine</z:chebi> cells </plain></SENT>
<SENT sid="7" pm="."><plain>METHODS: RT-PCR and chromatin immunoprecipitation (ChIP) were used to study Gip gene induction </plain></SENT>
<SENT sid="8" pm="."><plain>Gip promoter elements mediating WNT/<z:chebi fb="32" ids="30145">lithium</z:chebi> induction were identified (electrophoretic mobility shift assay, co-transfection of deletion mutants, ChIP) </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: <z:chebi fb="32" ids="30145">Lithium</z:chebi> or WNT/beta-catenin signalling enhanced GIP production by entero-<z:chebi fb="32" ids="24621">endocrine</z:chebi> cells through a conserved site in the proximal Gip promoter </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="32" ids="30145">Lithium</z:chebi> favours lymphoid enhancer factor-1/beta-catenin binding to Gip promoter and diminishes ChIP through T cell factor-4 and <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase 1 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: <z:chebi fb="32" ids="30145">Lithium</z:chebi> and WNT are incretin inducers in general </plain></SENT>
<SENT sid="12" pm="."><plain>This work provides a novel link between WNT signalling, <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>